You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT
SBC: ARGOLYN BIOSCIENCE, INC. Topic: N/AArgolyn Bioscience Inc. is an early stage biotechnology company that creates novel peptide drugs and diagnostics with greatly improved intrinsic pharmaceutical properties through substitution of non-natural amino acid analogues for arginine (Arg) or lysine (Lys). In proof-of concept studies thus far, application of the Argolyn technology to peptides of therapeutic interest has resulted in dramatic ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
NOVEL NEUROTENSIN ANALOGS AS ANTISCHIZOPRENICS
SBC: ARGOLYN BIOSCIENCE, INC. Topic: N/ADESCRIPTION (provided by applicant): The brain peptide neurotensin (NT) and its active derivative NT [8-13] function as endogenous neuroleptics. Stable NT derivatives that cross the blood brain barrier therefore have significant potential for development as a new class of non-dopamineric antipsychotics expected not to display the adverse side effects associated with the dopaminergics. The best lit ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF A BIOLOGICALLY-ACTIVE VASCULAR GRAFT
SBC: BIOMOD SURFACES Topic: N/AMedium (6-8mm) and small (
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF A BIOLOGICALLY-ACTIVE VASCULAR GRAFT
SBC: BIOMOD SURFACES Topic: N/AMedium (6-8mm) and small (
STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health -
NANOFIBER TECHNOLOGY IN SMALL-DIAMETER VASCULAR GRAFTS
SBC: BIOMOD SURFACES Topic: N/AThere is no small-diameter vascular prosthesis that is capable of emulating the biologic and physical properties of the normal arterial wall. The goal of this proposal is to develop a small-diameter prosthetic vascular graft using nanofiber technology. Our hypothesis is creating a nanofibrous vascular graft by electrospinning an ionic polyurethane will result in a graft that possesses properties s ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF A MIDDLE EAR BALLOON IMPLANT
SBC: BOSTON MEDICAL PRODUCTS, INC. Topic: N/ADESCRIPTION (provided by applicant): Development of a new type of middle ear implant, a "middle ear balloon" is proposed. This implant is intended to restore hearing in non-aerated ears by creating and permanently maintaining an air or gas-filled space within the middle ear. Non-aerated middle ears resulting from eustachian tube dysfunction camonly occur in chronic otitis media (COM) and in otitis ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF A MIDDLE EAR BALLOON IMPLANT
SBC: BOSTON MEDICAL PRODUCTS, INC. Topic: N/ADESCRIPTION (provided by applicant): Development of a new type of middle ear implant, a "middle ear balloon" is proposed. This implant is intended to restore hearing in non-aerated ears by creating and permanently maintaining an air or gas-filled space within the middle ear. Non-aerated middle ears resulting from eustachian tube dysfunction camonly occur in chronic otitis media (COM) and in otitis ...
STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health -
IDENTIFICATION AND EXPRESSION OF INSECTICIDE TARGETS
SBC: CAMBRIA BIOSCIENCES, LLC Topic: N/ADESCRIPTION (Provided by applicant): Insect-borne infectious diseases such as malaria affect at least 1 billion people worldwide, and over 1.5 million of these infected individuals die each year. Malarial parasites and many other vector-borne pathogens have developed resistance to current drugs, and vaccines are not available or feasible for many of these pathogens. Insect vector control programs ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
ORAL THERAPEUTIC FOR INDUCING FETAL HEMOGLOBIN
SBC: Gene Regulation Laboratories Topic: N/ADESCRIPTION (provided by applicant): Sickle cell disease (SCD) and beta-thalassemia are genetic disorders caused by molecular mutations affecting the genes for adult hemoglobin. With a world-wide birth prevalence of 2/1,000, hemoglobin disorders are the most common genetic diseases in the world (360,000 patients/year - 250,000 with sickling disorders and 110,000 with thalassemias. These conditions ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
ORAL THERAPEUTIC FOR INDUCING FETAL HEMOGLOBIN
SBC: Gene Regulation Laboratories Topic: N/ADESCRIPTION (provided by applicant): Sickle cell disease (SCD) and beta-thalassemia are genetic disorders caused by molecular mutations affecting the genes for adult hemoglobin. With a world-wide birth prevalence of 2/1,000, hemoglobin disorders are the most common genetic diseases in the world (360,000 patients/year - 250,000 with sickling disorders and 110,000 with thalassemias. These conditions ...
STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
